Literature DB >> 17188250

Excess ribonucleotide reductase R2 subunits coordinate the S phase checkpoint to facilitate DNA damage repair and recovery from replication stress.

Z Ping Lin1, Michael F Belcourt, Rocco Carbone, Jana S Eaton, Philip G Penketh, Gerald S Shadel, Joseph G Cory, Alan C Sartorelli.   

Abstract

Ribonucleotide reductase (RNR), which consists of R1 and R2 subunits, catalyzes a key step of deoxyribonucleoside triphosphate (dNTP) synthesis for DNA replication and repair. The R2 subunit is controlled in a cell cycle-specific manner for timely DNA synthesis and is negatively regulated by p53 in response to DNA damage. Herein we demonstrate that the presence of excess R2 subunits in p53(-/-) HCT-116 human colon cancer cells protects against DNA damage and replication stress. siRNA-mediated stable knockdown (>80%) of excess R2 subunits has no effect on proliferative growth but results in enhanced accumulation of gamma-H2Ax and delayed recovery from DNA lesions inflicted by exposure to cisplatin and Triapine. This accentuated induction of gamma-H2Ax in R2-knockdown cells is attributed to reduced ability to repair damaged DNA and overcome replication blockage. The lack of excess R2 subunits consequently augments chk1 activation and cdc25A degradation, causing impeded cell progression through the S phase and enhanced apoptosis in response to DNA damage and replication stress. In contrast, the level of R1 subunits appears to be limiting, since depletion of the R1 subunit directly activates the S phase checkpoint due to replication stress associated with impaired RNR activity. These findings suggest that excess R2 subunits facilitate DNA damage repair and recovery from replication stress through coordination with the S phase checkpoint in the absence of functional p53. Thus, the level of the R2 subunit constitutes an important determinant of the chemosensitivity of cancer cells and serves as a potential target for enhancement of DNA-damage based therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17188250     DOI: 10.1016/j.bcp.2006.11.014

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  21 in total

1.  Characterization of the behavior of functional viral genomes during the early steps of human immunodeficiency virus type 1 infection.

Authors:  Vanessa Arfi; Julia Lienard; Xuan-Nhi Nguyen; Gregory Berger; Dominique Rigal; Jean-Luc Darlix; Andrea Cimarelli
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

2.  Triapine disrupts CtIP-mediated homologous recombination repair and sensitizes ovarian cancer cells to PARP and topoisomerase inhibitors.

Authors:  Z Ping Lin; Elena S Ratner; Margaret E Whicker; Yashang Lee; Alan C Sartorelli
Journal:  Mol Cancer Res       Date:  2014-01-10       Impact factor: 5.852

3.  Phase I/II multisite trial of optimally dosed clofarabine and low-dose TBI for hematopoietic cell transplantation in acute myeloid leukemia.

Authors:  Elizabeth F Krakow; Boglarka Gyurkocza; Barry E Storer; Thomas R Chauncey; Jeannine S McCune; Jerald P Radich; Michelle E Bouvier; Elihu H Estey; Rainer Storb; David G Maloney; Brenda M Sandmaier
Journal:  Am J Hematol       Date:  2019-11-08       Impact factor: 10.047

4.  Novel immunosuppressive agent caerulomycin A exerts its effect by depleting cellular iron content.

Authors:  Suneet Kaur; Gautam Srivastava; Amar Nath Sharma; Ravinder S Jolly
Journal:  Br J Pharmacol       Date:  2015-02-10       Impact factor: 8.739

5.  Reduced level of ribonucleotide reductase R2 subunits increases dependence on homologous recombination repair of cisplatin-induced DNA damage.

Authors:  Z Ping Lin; Yashang Lee; Fang Lin; Michael F Belcourt; Peining Li; Joseph G Cory; Peter M Glazer; Alan C Sartorelli
Journal:  Mol Pharmacol       Date:  2011-08-29       Impact factor: 4.436

6.  Disruption of cAMP and prostaglandin E2 transport by multidrug resistance protein 4 deficiency alters cAMP-mediated signaling and nociceptive response.

Authors:  Z Ping Lin; Yong-Lian Zhu; Dennis R Johnson; Kevin P Rice; Timothy Nottoli; Bryan C Hains; James McGrath; Stephen G Waxman; Alan C Sartorelli
Journal:  Mol Pharmacol       Date:  2007-10-24       Impact factor: 4.436

7.  Bcl2 induces DNA replication stress by inhibiting ribonucleotide reductase.

Authors:  Maohua Xie; Yun Yen; Taofeek K Owonikoko; Suresh S Ramalingam; Fadlo R Khuri; Walter J Curran; Paul W Doetsch; Xingming Deng
Journal:  Cancer Res       Date:  2013-11-06       Impact factor: 12.701

8.  Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein.

Authors:  Charles A Kunos; Song-mao Chiu; John Pink; Timothy J Kinsella
Journal:  Radiat Res       Date:  2009-12       Impact factor: 2.841

9.  Ataxia-telangiectasia mutated kinase regulates ribonucleotide reductase and mitochondrial homeostasis.

Authors:  Jana S Eaton; Z Ping Lin; Alan C Sartorelli; Nicholas D Bonawitz; Gerald S Shadel
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

10.  Potent subunit-specific effects on cell growth and drug sensitivity from optimised siRNA-mediated silencing of ribonucleotide reductase.

Authors:  Glen Reid; Natacha Coppieters 't Wallant; Rachna Patel; Ana Antonic; Faamatala Saxon-Aliifaalogo; Helen Cao; Gill Webster; James D Watson
Journal:  J RNAi Gene Silencing       Date:  2009-03-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.